BioCryst Pharmaceuticals
BCRX
220 hedge funds and large institutions have $1.61B invested in BioCryst Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 71 increasing their positions, 60 reducing their positions, and 51 closing their positions.
90% more call options, than puts
Call options by funds: $51.3M | Put options by funds: $27M
18% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 60
12.59% more ownership
Funds ownership: 69.24% → 81.83% (+13%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
6% less funds holding
Funds holding: 233 → 220 (-13)
18% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 51
23% less capital invested
Capital invested by funds: $2.09B → $1.61B (-$487M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$47.7M |
| 2 |
Morgan Stanley
New York
|
+$37.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$36.5M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$34.5M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$32.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$38.3M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$37.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$33.3M |
| 4 |
DM
Deerfield Management
New York
|
-$16.5M |
| 5 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$11.5M |
BCRX Hedge Fund Activity: Q2 2022 in Review
220 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2022, worth a combined $1.61B — down 23% from $2.09B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of BCRX and 42 opened new positions — a net loss of 9 holders — while 60 trimmed existing stakes and 71 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $47.7M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $38.3M sold.
- 220 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2022, down from 233 in Q1 2022.
- Funds reported $1.61B of BioCryst Pharmaceuticals stock for Q2 2022, down 23% quarter-over-quarter.
- 42 funds opened new BioCryst Pharmaceuticals positions in Q2 2022 and 51 closed out, a net change of -9 holders.
- The largest BioCryst Pharmaceuticals buyer in Q2 2022 was Avoro Capital Advisors, an estimated $47.7M added.
- The largest BioCryst Pharmaceuticals seller in Q2 2022 was Loomis, Sayles & Company, an estimated $38.3M sold.
Based on aggregated 13F filings for Q2 2022.